Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 4/2024

31.01.2024 | REVIEW

Exploring Technology’s Influence on Health Behaviours and Well-being in Type 1 Diabetes: a Review

verfasst von: Reid D. McClure, Meryem K. Talbo, Anne Bonhoure, Joséphine Molveau, Courtney A. South, Maha Lebbar, Zekai Wu

Erschienen in: Current Diabetes Reports | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Maintaining positive health behaviours promotes better health outcomes for people with type 1 diabetes (T1D). However, implementing these behaviours may also lead to additional management burdens and challenges. Diabetes technologies, including continuous glucose monitoring systems, automated insulin delivery systems, and digital platforms, are being rapidly developed and widely used to reduce these burdens. Our aim was to review recent evidence to explore the influence of these technologies on health behaviours and well-being among adults with T1D and discuss future directions.

Recent Findings

Current evidence, albeit limited, suggests that technologies applied in diabetes self-management education and support (DSME/S), nutrition, physical activity (PA), and psychosocial care areas improved glucose outcomes. They may also increase flexibility in insulin adjustment and eating behaviours, reduce carb counting burden, increase confidence in PA, and reduce mental burden.

Summary

Technologies have the potential to promote health behaviours changes and well-being for people with T1D. More confirmative studies on their effectiveness and safety are needed to ensure optimal integration in standard care practices.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741–60.PubMedCrossRef
2.
Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: overview. Diabetes Care. 2014;37(1):9–16.PubMedCrossRef
3.
Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2021;44(11):2589–625
4.
American Diabetes Association. Standards of medical care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S1-291.
5.
Brazeau AS, Messier V, Talbo MK, Gagnon C, Taleb N, Fortier I, et al. Self-reported severe and nonsevere hypoglycemia in type 1 diabetes: population surveillance through the BETTER Patient Engagement Registry: development and baseline characteristics. Can J Diabetes. 2022;46(8):813–21.PubMedCrossRef
6.
Wu ZK, Jin TR, Weng JP. A thorough analysis of diabetes research in China from 1995 to 2015: current scenario and future scope. Sci China Life Sci. 2019;62(1):46–62.PubMedCrossRef
7.
Miller KM, Hermann J, Foster N, Hofer SE, Rickels MR, Danne T, et al. Longitudinal changes in continuous glucose monitoring use among individuals with type 1 diabetes: international comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care. 2020;43(1):e1-e2
8.
Beck RW, Bergenstal RM, Laffel LM, Pickup JC. Advances in technology for management of type 1 diabetes. Lancet. 2019;394(10205):1265–73.PubMedCrossRef
9.
Nc F, Rw B, Km M, Ma C, Mr R, La D, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72.CrossRef
10.
Ling P, Yan J, Yang D, Luo S, Zheng X, Wu Z, et al. Current state of type 1 diabetes in China: an analysis from a mobile health application TangTangQuan based database. Diabetologia. 2019;62:S394-S
11.
12.
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20.PubMedCrossRef
13.
Braune K, Lal RA, Petruzelkova L, Scheiner G, Winterdijk P, Schmidt S, et al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol. 2022;10(1):58–74.PubMedCrossRef
14.
Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. J Acad Nutr Diet. 2015;115(8):1323–34.PubMedCrossRef
15.
Rankin D, Cooke DD, Elliott J, Heller SR, Lawton J, the UKNDSG. Supporting self-management after attending a structured education programme: a qualitative longitudinal investigation of type 1 diabetes patients’ experiences and views. BMC Public Health. 2012;12(1):652.
16.
Winkley K, Evwierhoma C, Amiel SA, Lempp HK, Ismail K, Forbes A. Patient explanations for non-attendance at structured diabetes education sessions for newly diagnosed Type 2 diabetes: a qualitative study. Diabet Med. 2015;32(1):120–8.PubMedCrossRef
17.
•• Liu Z, Wang C, Yang D, Luo S, Ding Y, Xu W, et al. High engagement in mobile peer support is associated with better glycemic control in type 1 diabetes: a real-world study. J Diabetes Investig. 2022;13(11):1914–24. A large sample study suggesting that 12 months’ use of a mobile application improved glucose management, especially among those more engaged in peer support
18.
Xie LF, Roy-Fleming A, Haag S, Costa DD, Brazeau AS. Development of the support self-guided, web application for adults living with type 1 diabetes in Canada by a multi-disciplinary team using a people-oriented approach based on the Behaviour Change Wheel. Digit Health. 2023;9:20552076231152760.PubMedPubMedCentral
19.
20.
Lane W, Lambert E, George J, Rathor N, Thalange N. Exploring the burden of mealtime insulin dosing in adults and children with type 1 diabetes. Clin Diabetes. 2021;39(4):347–57.PubMedPubMedCentralCrossRef
21.
Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731–54.PubMedPubMedCentralCrossRef
22.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 5 Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Supple 1):S68-s96.
23.
24.
American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S85-S99
25.
•• Waldenmaier D, Freckmann G, Pleus S, Hermanns N, Ehrmann D, Heinemann L, et al. Therapy adjustments in people with type 1 diabetes with impaired hypoglycemia awareness on multiple daily injections using real-time continuous glucose monitoring: a mechanistic analysis of the HypoDE study. BMJ Open Diabetes Res Care. 2021;9(1). First large RCT showing additional possible benefit of rt-CGM to intercept an upcoming hypoglycaemia while reducing the amount of simple carbohydrate needed.
26.
Pinsker JE, Bartee A, Katz M, Lalonde A, Jones R, Dassau E, et al. Predictive low-glucose suspend necessitates less carbohydrate supplementation to rescue hypoglycemia: need to revisit current hypoglycemia treatment guidelines. Diabetes Technol Ther. 2021;23(7):512–6.PubMedPubMedCentralCrossRef
27.
• Wallace T, Heath J, Koebbel C. The impact of flash glucose monitoring on adults with type 1 diabetes’ eating habits and relationship with food. Diabetes Res Clin Pract. 2023;196:110230. A novel qualitative study exploring the impact of isCGM on people with type 1 diabetes’ relationship with food.
28.
Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al. Effects of flash glucose monitoring on dietary variety, physical activity, and self-care behaviors in patients with diabetes. J Diabetes Res. 2020;2020:9463648.PubMedPubMedCentralCrossRef
29.
Priesterroth L, Grammes J, Clauter M, Kubiak T. Diabetes technologies in people with type 1 diabetes mellitus and disordered eating: a systematic review on continuous subcutaneous insulin infusion, continuous glucose monitoring and automated insulin delivery. Diabet Med. 2021;38(7):e14581.PubMedCrossRef
30.
Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health. 2015;73:43.PubMedPubMedCentralCrossRef
31.
Haidar A, Legault L, Raffray M, Gouchie-Provencher N, Jafar A, Devaux M, et al. A randomized crossover trial to compare automated insulin delivery (the artificial pancreas) with carbohydrate counting or simplified qualitative meal-size estimation in type 1 diabetes. Diabetes Care. 2023;46(7):1372–8.PubMedPubMedCentralCrossRef
32.
•• Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, et al. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387(13):1161–72. Large RCT assessing a novel technology (bionic pancreas) requiring minimal input from the user
33.
Al Balwi R, Al Madani W, Al GA. Efficacy of insulin dosing algorithms for high-fat high-protein mixed meals to control postprandial glycemic excursions in people living with type 1 diabetes: A systematic review and meta-analysis. Pediatr Diabetes. 2022;23(8):1635–46.PubMedCrossRef
34.
Metwally M, Cheung TO, Smith R, Bell KJ. Insulin pump dosing strategies for meals varying in fat, protein or glycaemic index or grazing-style meals in type 1 diabetes: a systematic review. Diabetes Res Clin Pract. 2021;172:108516.PubMedCrossRef
35.
McKnight JA, Ochs A, Mair C, McKnight O, Wright R, Gibb FW, et al. The effect of DAFNE education, continuous subcutaneous insulin infusion, or both in a population with type 1 diabetes in Scotland. Diabet Med. 2020;37(6):1016–22.PubMedCrossRef
36.
Gingras V, Bonato L, Messier V, Roy-Fleming A, Smaoui MR, Ladouceur M, et al. Impact of macronutrient content of meals on postprandial glucose control in the context of closed-loop insulin delivery: a randomized cross-over study. Diabetes Obes Metab. 2018;20(11):2695–9.PubMedCrossRef
37.
Lehmann V, Zueger T, Zeder A, Scott S, Bally L, Laimer M, et al. Lower daily carbohydrate intake is associated with improved glycemic control in adults with type 1 diabetes using a hybrid closed-loop system. Diabetes Care. 2020;43(12):3102–5.PubMedCrossRef
38.
Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000;23(7):943–50.PubMedCrossRef
39.
Kebede MM, Pischke CR. Popular diabetes apps and the impact of diabetes app use on self-care behaviour: a survey among the digital community of persons with diabetes on social media. Front Endocrinol (Lausanne). 2019;10:135.PubMedCrossRef
40.
Bohn B, Herbst A, Pfeifer M, Krakow D, Zimny S, Kopp F, et al. Impact of physical activity on glycemic control and prevalence of cardiovascular risk factors in adults with type 1 diabetes: a cross-sectional multicenter study of 18,028 patients. Diabetes Care. 2015;38(8):1536–43.PubMedCrossRef
41.
42.
Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008;31(11):2108–9.PubMedPubMedCentralCrossRef
43.
Parent C, Lespagnol E, Berthoin S, Tagougui S, Heyman J, Stuckens C, et al. Barriers to physical activity in children and adults living with type 1 diabetes: a complex link with real-life glycemic excursions. Can J Diabetes. 2023;47(2):124–32.PubMedCrossRef
44.
Moser O, Riddell MC, Eckstein ML, Adolfsson P, Rabasa-Lhoret R, van den Boom L, et al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia. 2020;63(12):2501–20.PubMedCrossRef
45.
Hásková A, Radovnická L, Petruželková L, Parkin CG, Grunberger G, Horová E, et al. Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial. Diabetes Care. 2020;43(11):2744–50.PubMedPubMedCentralCrossRef
46.
Marion F, van Peter D, Mireille E, Eglantine B, Jeanine M, Robbert S, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7(1):e000809.CrossRef
47.
48.
Nystrom T, Schwarz E, Dahlqvist S, Wijkman M, Ekelund M, Holmer H, et al. Evaluation of effects of continuous glucose monitoring on physical activity habits and blood lipid levels in persons with type 1 diabetes managed with MDI: an analysis based on the GOLD randomized trial (GOLD 8). J Diabetes Sci Technol. 2022:19322968221101916
49.
Biagi L, Bertachi A, Quirós C, Giménez M, Conget I, Bondia J, Vehí J. Accuracy of continuous glucose monitoring before, during, and after aerobic and anaerobic exercise in patients with type 1 diabetes mellitus. Biosensors (Basel). 2018;8(1):22. https://​doi.​org/​10.​3390/​bios8010022.
50.
• Da Prato G, Pasquini S, Rinaldi E, Lucianer T, Donà S, Santi L, et al. Accuracy of CGM systems during continuous and interval exercise in adults with type 1 diabetes. J Diabetes Sci Technol. 2022;16(6):1436–43. Prospective study suggesting concerning findings that commercially available systems showed lower accuracy than claimed during inpatient exercise testing, especially for continuous exercise.
51.
Fokkert M, van Dijk PR, Edens MA, Díez Hernández A, Slingerland R, Gans R, Delgado Álvarez E, Bilo H. Performance of the Eversense versus the Free-Style Libre Flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8(1):e001193. https://​doi.​org/​10.​1136/​bmjdrc-2020-001193.
52.
Fokkert MJ, van Dijk PR, Edens MA, Díez A, Slingerland RJ, Gans ROB, et al. Performance of continuous glucose monitoring devices during intensive exercise conditions in people with diabetes: the Mont Blanc experience. Diabet Med. 2020;37(7):1204–5.PubMedCrossRef
53.
Hanaire H, Franc S, Borot S, Penfornis A, Benhamou P-Y, Schaepelynck P, et al. Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. Diabetes Obes Metab. 2020;22(3):324–34.PubMedCrossRef
54.
Tagougui S, Taleb N, Legault L, Suppere C, Messier V, Boukabous I, et al. A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies. Diabetologia. 2020;63(11):2282–91.PubMedCrossRef
55.
Paldus B, Morrison D, Zaharieva DP, Lee MH, Jones H, Obeyesekere V, et al. A randomized crossover trial comparing glucose control during moderate-intensity, high-intensity, and resistance exercise with hybrid closed-loop insulin delivery while profiling potential additional signals in adults with type 1 diabetes. Diabetes Care. 2022;45(1):194–203.PubMedCrossRef
56.
Myette-Cote E, Molveau J, Wu Z, Raffray M, Devaux M, Tagougui S, et al. A randomized crossover pilot study evaluating glucose control during exercise initiated 1 or 2 h after a meal in adults with type 1 diabetes treated with an automated insulin delivery system. Diabetes Technol Ther. 2023;25(2):122–30.PubMedPubMedCentralCrossRef
57.
Cho S, Aiello EM, Ozaslan B, Riddell MC, Calhoun P, Gal RL, Doyle FJ 3rd. Design of a real-time physical activity detection and classification framework for individuals with type 1 diabetes. J Diabetes Sci Technol. 2023;17:19322968231153896. https://​doi.​org/​10.​1177/​1932296823115389​6.
58.
Turksoy K, Hajizadeh I, Hobbs N, Kilkus J, Littlejohn E, Samadi S, et al. Multivariable artificial pancreas for various exercise types and intensities. Diabetes Technol Ther. 2018;20(10):662–71.PubMedPubMedCentralCrossRef
59.
Wilson LM, Jacobs PG, Ramsey KL, Resalat N, Reddy R, Branigan D, et al. Dual-hormone closed-loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial. Diabetes Care. 2020;43(11):2721–9.PubMedCrossRef
60.
• Wu Z, Yardley JE, Messier V, Legault L, Grou C, Rabasa-Lhoret R. Comparison of nocturnal glucose after exercise among dual-hormone, single-hormone algorithm-assisted insulin delivery system and usual care in adults and adolescents living with type 1 diabetes: a pooled analysis. Diabetes Technol Ther. 2022;24(10):754–62. Pooled analysis including all available studies suggesting that dual-hormone automated insulin delivery (AID) systems allow improved postexercise nocturnal glycaemic management than single-hormone AID or usual care among adults with type 1 diabetes.
61.
Taleb N, Quintal A, Rakheja R, Messier V, Legault L, Racine E, et al. Perceptions and expectations of adults with type 1 diabetes for the use of artificial pancreas systems with and without glucagon addition: results of an online survey. Nutr Metab Cardiovasc Dis. 2021;31(2):658–65.PubMedCrossRef
62.
Wu Z, Lebbar M, Taleb N, Legault L, Messier V, Rabasa-Lhoret R. Comparing dual-hormone and single-hormone automated insulin delivery systems on nocturnal glucose management among children and adolescents with type 1 diabetes: a pooled analysis. Diabetes, Obes Metab. 2022;25(1):310–3.PubMedCrossRef
63.
Piotrowicz AK, McGill MJ, Overland J, Molyneaux L, Johnson NA, Twigg SM. An on-line support tool to reduce exercise-related hypoglycaemia and improve confidence to exercise in type 1 diabetes. J Diabetes Complications. 2019;33(9):682–9.PubMedCrossRef
64.
65.
Durlach V, Vergès B, Al-Salameh A, Bahougne T, Benzerouk F, Berlin I, et al. Smoking and diabetes interplay: a comprehensive review and joint statement. Diabetes Metab. 2022;48(6):101370.PubMedCrossRef
66.
World Health Organization. WHO global report on trends in prevalence of tobacco use 2000-2025, 4th edn. Geneva: World Health Organization; 2021.
67.
Campagna D, Alamo A, Di Pino A, Russo C, Calogero AE, Purrello F, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2019;11(1):85.PubMedPubMedCentralCrossRef
68.
Jensen MH, Cichosz SL, Hirsch IB, Vestergaard P, Hejlesen O, Seto E. Smoking is associated with increased risk of not achieving glycemic target, increased glycemic variability, and increased risk of hypoglycemia for people with type 1 diabetes. J Diabetes Sci Technol. 2021;15(4):827–32.PubMedCrossRef
69.
70.
Nail K, Martinez S, Terry R, Ice S, Keener S, Ritter T, Nolan D. Feasibility of using biomarkers to examine associations between commercial cigarette smoking and glycemic levels during a smoking cessation attempt. In: Poster presented at Research Week. Tulsa, OH: Oklahoma State University Center for Health Sciences; 2023.
71.
72.
Olano-Espinosa E, Avila-Tomas JF, Minue-Lorenzo C, Matilla-Pardo B, Serrano ME, Martinez-Suberviola FJ, et al. Effectiveness of a conversational chatbot (Dejal@bot) for the adult population to quit smoking: pragmatic, multicenter, controlled, randomized clinical trial in primary care. JMIR Mhealth Uhealth. 2022;10(6):e34273.PubMedPubMedCentralCrossRef
73.
Fisher L, Hessler D, Polonsky W, Strycker L, Masharani U, Peters A. Diabetes distress in adults with type 1 diabetes: prevalence, incidence and change over time. J Diabetes Complications. 2016;30(6):1123–8.PubMedPubMedCentralCrossRef
74.
Trief PM, Xing D, Foster NC, Maahs DM, Kittelsrud JM, Olson BA, et al. Depression in adults in the T1D Exchange Clinic Registry. Diabetes Care. 2014;37(6):1563–72.PubMedCrossRef
75.
Bakker JJ, Lameijer A, Flores Guerrero JL, Bilo HJG, van Dijk PR. Commencement of flash glucose monitoring is associated with a decreased rate of depressive disorders among persons with diabetes (FLARE-NL7). BMJ Open Diabetes Res Care. 2022;10(3):e002769. https://​doi.​org/​10.​1136/​bmjdrc-2022-002769.
76.
Charleer S, De Block C, Van Huffel L, Broos B, Fieuws S, Nobels F, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2019;43(2):dc191610.
77.
Charleer S, De Block C, Nobels F, Radermecker RP, Lowyck I, Mullens A, Scarnière D, Spincemaille K, Strivay M, Weber E, Taes Y, Vercammen C, Keymeulen B, Mathieu C, Gillard P; RESCUE Trial Investigators. Sustained impact of real-time continuous glucose monitoring in adults with type 1 diabetes on insulin pump therapy: results after the 24-month RESCUE study. Diabetes Care. 2020;43(12):3016–23. https://​doi.​org/​10.​2337/​dc20-1531.
78.
Lukacs A, Szerencsi LB, Barkai L. Continuous glucose monitoring (CGM) satisfaction and its effect on mental health and glycemic control in adults with type 1 diabetes. Physiol Int. 2022;109(4):501–10.PubMed
79.
Beato-Vibora PI, Gallego-Gamero F, Ambrojo-Lopez A, Gil-Poch E, Martin-Romo I, Arroyo-Diez FJ. Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting. Diabetes Res Clin Pract. 2021;178:108986.PubMedCrossRef
80.
Boscari F, Ferretto S, Cavallin F, Bruttomesso D. Switching from predictive low glucose suspend to advanced hybrid closed loop control: effects on glucose control and patient reported outcomes. Diabetes Res Clin Pract. 2022;185:109784.PubMedCrossRef
81.
Kubilay E, Trawley S, Ward GM, Fourlanos S, Grills CA, Lee MH, et al. Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial. Diabet Med. 2023;40(4):e15020.PubMedCrossRef
82.
83.
Wu Z, Luo S, Zheng X, Bi Y, Xu W, Yan J, et al. Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes. Ther Adv Endocrinol Metab. 2020;11:2042018820950146.PubMedPubMedCentralCrossRef
84.
Pinsker JE, Müller L, Constantin A, Leas S, Manning M, McElwee Malloy M, et al. Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther. 2021;23(2):120–7.PubMedPubMedCentralCrossRef
85.
Matejko B, Juza A, Kieć-Wilk B, Cyranka K, Krzyżowska S, Chen X, et al. Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed-loop system: a two-center, randomized, controlled study. Diabetes Care. 2022;45(11):2628–35.PubMedPubMedCentralCrossRef
86.
Patel R, Crabtree TSJ, Taylor N, Langeland L, Gazis AT, Mendis B, Wilmot EG, Idris I. Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with freestyle libre in people with type 1 diabetes. Diabet Med. 2022;39(5):e14793. https://​doi.​org/​10.​1111/​dme.​14793.
87.
Cyranka K, Matejko B, Juza A, Kieć-Wilk B, Krzyżowska S, Cohen O, et al. Improvement of selected psychological parameters and quality of life of patients with type 1 diabetes mellitus undergoing transition from multiple daily injections and self-monitoring of blood glucose directly to the MiniMed 780G advanced hybrid closed-loop system: post hoc analysis of a randomized control study. JMIR Form Res. 2023;7:e43535.PubMedPubMedCentralCrossRef
88.
Bisio A, Gonder-Frederick L, McFadden R, Chernavvsky D, Voelmle M, Pajewski M, et al. The impact of a recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with type 1 diabetes: a pilot study. J Diabetes Sci Technol. 2022;16(3):663–9.PubMedCrossRef
89.
•• Polonsky WH, Hood KK, Levy CJ, MacLeish SA, Hirsch IB, Brown SA, et al. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod R 5 System. Diabetes Res Clin Pract. 2022;190:109998. Large sample study suggesting that using an automated insulin delivery system for 3 months significantly improved confidence in hypoglycaemia management and diabetes distress.
90.
Thabit H, Boughton C, Mubita W, Rubio J, Mader JK, Narendran P, et al. Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes. Diabetes Obes Metab. 2023;25(3):889–93.PubMedCrossRef
91.
Chakrabarti A, Trawley S, Kubilay E, Mohammad Alipoor A, Vogrin S, Fourlanos S, et al. Closed-loop insulin delivery effects on glycemia during sleep and sleep quality in older adults with type 1 diabetes: results from the ORACL trial. Diabetes Technol Ther. 2022;24(9):666–71.PubMedCrossRef
92.
Bisno DI, Reid MW, Fogel JL, Pyatak EA, Majidi S, Raymond JK. Virtual group appointments reduce distress and improve care management in young adults with type 1 diabetes. J Diabetes Sci Technol. 2022;16(6):1419–27.PubMedCrossRef
93.
Bakhach M, Reid MW, Pyatak EA, Berget C, Cain C, Thomas J, et al. Home telemedicine (CoYoT1 Clinic): a novel approach to improve psychosocial outcomes in young adults with diabetes. Diabetes Educ. 2019;45(4):420–30.PubMedCrossRef
94.
• Doherty AM, Herrmann-Werner A, Rowe A, Brown J, Weich S, Ismail K. Feasibility study of real-time online text-based CBT to support self-management for people with type 1 diabetes: the Diabetes On-line Therapy (DOT) Study. BMJ Open Diabetes Res. 2021;9(1):01. The only recent study investigated that integrating online text–based therapy into the treatment plan of adults with T1D improved glycaemic management and anxiety.
95.
Martyn-Nemeth P, Duffecy J, Quinn L, Steffen A, Baron K, Chapagai S, et al. Sleep-opt-in: a randomized controlled pilot study to improve sleep and glycemic variability in adults with type 1 diabetes. Sci Diabetes Self Manag Care. 2023;49(1):11–22.PubMedCrossRef
96.
Talbo MK, Katz A, Peters T, Yale J-F, Wu Z, Brazeau A-S. 660-P: the effect of real-time continuous glucose monitors on fear of hypoglycemia in people with type 1 diabetes: a systematic review and meta-analysis. Diabetes. 2022;71(Supplement_1):660–P. https://​doi.​org/​10.​2337/​db22-660-P.
97.
Talbo MK, Katz A, Hill L, Peters TM, Yale JF, Brazeau AS. Effect of diabetes technologies on the fear of hypoglycaemia among people living with type 1 diabetes: a systematic review and meta-analysis. EClinicalMedicine. 2023;62:102119.PubMedPubMedCentralCrossRef
98.
Chinese Diabetes Society, Chinese Endocrinologist Association, Chinese Society of Endocrinology, Chinese Pediatric Society. Guidelines for the diagnosis and treatment of type 1 diabetes mellitus in China (2021 edition). Chin J Diabetes Mellitus. 2022;14(11):1143–250.
99.
Wu Z, Bandini A, Brazeau AS, Rabasa-Lhoret R. Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs), it’s time to give more credits to patients’ voice in research: the example of assessing hypoglycemia burden. Diabetes Metab. 2023;49(2):101417.PubMedCrossRef
100.
Wu Z, Talbo M, Lebbar M, Messier V, Courchesne A, Brazeau AS, et al. Characteristics associated with having a hemoglobin A1c ≤ 7 % (≤53 mmol/mol) among adults with type 1 diabetes using an automated insulin delivery system. Diabetes Res Clin Pract. 2023;206:111006.PubMedCrossRef
Metadaten
Titel
Exploring Technology’s Influence on Health Behaviours and Well-being in Type 1 Diabetes: a Review
verfasst von
Reid D. McClure
Meryem K. Talbo
Anne Bonhoure
Joséphine Molveau
Courtney A. South
Maha Lebbar
Zekai Wu
Publikationsdatum
31.01.2024
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 4/2024
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-024-01534-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise